Evidence map›Paper›PMID 32852745›Full record

SynthesisDrugs2020

Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review.

N Ghalandari, R J E M Dolhain, J M W Hazes, E P van Puijenbroek, M Kapur, H J M J Crijns

Open access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. TNF-Expert reviews in molecular medicine · 2022
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

N GhalandariDepartment of Rheumatology, Erasmus University Medical Center, Rotterdam, The Netherlands. n.ghalandari@erasmusmc.nl.ORCID http://orcid.org/0000-0002-7130-2749
R J E M DolhainDepartment of Rheumatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
J M W HazesDepartment of Rheumatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
E P van PuijenbroekNetherlands Pharmacovigilance Centre Lareb, 's Hertogenbosch, The Netherlands.
M KapurUtrecht University of Medical Sciences, Utrecht, The Netherlands.
H J M J CrijnsMedicines Evaluation Board (MEB), Graadt van Roggenweg 500, 3531 AH, Utrecht, The Netherlands.
Erasmus MC · NLMedicines Evaluation Board · NLNetherlands Pharmacovigilance Centre Lareb · NLUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory autoimmune diseases are chronic diseases that often affect women of childbearing age. Therefore, detailed knowledge of the safety profile of medications used for management of inflammatory autoimmune diseases during pregnancy is important. However, in many cases the potential harmful effects of medications (especially biologics) during pregnancy (and lactation) on mother and child have not been fully identified.

objectiveOur aim was to update the data on the occurrence of miscarriages and (major) congenital malformations when using biologics during pregnancy based on newly published articles. Additionally, we selected several different secondary outcomes that may be of interest for clinicians, especially information on adverse events in the use of a specific biologic during pregnancy. MATERIAL AND

methodsA search was conducted from 1 January 2015 until 4 July 2019 in Embase.com, Medline Ovid, Web of Science, Cochrane CENTRAL, and Google Scholar with specific search terms for each database. Selection of publications was based on title/abstract and followed by full text (double blinded, two researchers). An overview was made based on outcomes of interest. References of the included publications were reviewed to include and minimize the missing publications.

resultsA total of 143 publications were included. The total number of cases ranged from nine for canakinumab to 4276 for infliximab. The rates of miscarriages and major congenital malformations did not show relevant differences from those rates in the general population.

conclusionDespite limitations to our study, no major safety issues were reported and no trend could be identified in the reported malformations.

Indexed as

Maternal-Fetal ExchangeAbnormalities, Drug-InducedAbortion, SpontaneousAntibodies, Monoclonal, HumanizedAutoimmune DiseasesBiological ProductsFemaleHumansInflammationInfliximabPregnancyAntibodies, Monoclonal, HumanizedBiological ProductscanakinumabInfliximab

Identifiers

PMID32852745
PMCPMC7568712
OpenAlexW3081467449

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.